What is Lifesci Capital’s Estimate for GLUE FY2024 Earnings?

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) – Investment analysts at Lifesci Capital issued their FY2024 earnings per share (EPS) estimates for Monte Rosa Therapeutics in a note issued to investors on Wednesday, March 12th. Lifesci Capital analyst O. Mccammon expects that the company will post earnings per share of ($2.00) for the year. Lifesci Capital currently has a “Outperform” rating and a $19.00 target price on the stock. The consensus estimate for Monte Rosa Therapeutics’ current full-year earnings is ($1.49) per share. Lifesci Capital also issued estimates for Monte Rosa Therapeutics’ Q4 2024 earnings at ($0.66) EPS.

Separately, Wells Fargo & Company downgraded Monte Rosa Therapeutics from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $14.00 to $11.00 in a research report on Thursday, December 19th.

Monte Rosa Therapeutics Trading Up 1.0 %

Shares of GLUE stock opened at $6.27 on Friday. The business’s 50-day moving average price is $6.14 and its 200-day moving average price is $6.76. Monte Rosa Therapeutics has a 12 month low of $3.21 and a 12 month high of $12.40. The firm has a market capitalization of $385.21 million, a price-to-earnings ratio of -3.43 and a beta of 1.50.

Hedge Funds Weigh In On Monte Rosa Therapeutics

Hedge funds have recently made changes to their positions in the stock. Tower Research Capital LLC TRC increased its holdings in Monte Rosa Therapeutics by 192.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,443 shares of the company’s stock worth $38,000 after purchasing an additional 3,584 shares in the last quarter. GAMMA Investing LLC increased its holdings in Monte Rosa Therapeutics by 10,665.5% in the fourth quarter. GAMMA Investing LLC now owns 5,921 shares of the company’s stock worth $41,000 after purchasing an additional 5,866 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in Monte Rosa Therapeutics in the fourth quarter worth approximately $43,000. Virtus ETF Advisers LLC bought a new stake in Monte Rosa Therapeutics in the fourth quarter worth approximately $63,000. Finally, Intech Investment Management LLC bought a new stake in Monte Rosa Therapeutics in the third quarter worth approximately $77,000. 79.96% of the stock is currently owned by institutional investors.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.